EP Patent

EP3351541A1 — Metalloenzyme inhibitor compounds

Assigned to Mycovia Pharmaceuticals Inc · Expires 2018-07-25 · 8y expired

What this patent protects

The instant invention describes compounds having metalloenzyme modulating activity, and methods of treating diseases, disorders or symptoms thereof mediated by such metalloenzymes.

USPTO Abstract

The instant invention describes compounds having metalloenzyme modulating activity, and methods of treating diseases, disorders or symptoms thereof mediated by such metalloenzymes.

Drugs covered by this patent

Patent Metadata

Patent number
EP3351541A1
Jurisdiction
EP
Classification
—
Expires
2018-07-25
Drug substance claim
No
Drug product claim
No
Assignee
Mycovia Pharmaceuticals Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.